TD Cowen analyst Ryan Langston initiated coverage of Tenet Healthcare (THC) with a Buy rating and $175 price target Since 2021, Tenet has been on a “transformational journey,” divesting 19 hospitals and deleveraging significantly while growing consolidated facilities, the analyst tells investors in a research note. The firm believes management will continue to execute on their strategy of adding ambulatory surgery centers and higher acuity procedures across the portfolio.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on THC:
- Tenet Healthcare: Undervalued Potential and Strong Buy Rating Amidst LBO Comparisons
- Strong Buy Recommendation for Tenet Healthcare: Undervalued Stock with Robust Growth Potential and Positive Financial Outlook
- Tenet Healthcare’s 2024 Earnings Call Highlights Growth and Challenges
- Tenet Healthcare selloff overdone after Q4 earnings, says Cantor Fitzgerald
- Tenet Healthcare price target lowered to $161 from $190 at Barclays